Alison Daigle, DO
Neurology · South Portland, MENPI 1730476839
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $34,987 of the $49,911 with a category attached, or 70.1%. It is spread thinly across 38 manufacturers, the largest accounting for just 23.2%. Reporting peaked in 2019 at $20,928 and has fallen 63.6% since, to $7,628 in 2025. Among neurology clinicians in ME with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 387 payments — averaging $128.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$12K
- Biogen$10K
- EMD Serono, Inc.$9K
- Sanofi$8K
- Argenx US, Inc.$6K
- AbbVie$2K
- plus $3K from 32 others
What the payments were for
- Consulting fees$34,98770%
- Speaking & faculty fees$660%
- Travel & lodging$5,49111%
- Food & beverage$9,13518%
- Education$2320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 22 | $11,566 |
| Biogen | 49 | $10,291 |
| EMD Serono, Inc. | 59 | $8,537 |
| Sanofi | 27 | $8,348 |
| Argenx US, Inc. | 10 | $6,365 |
| AbbVie(2 entities) | 92 | $1,662 |
| Novartis | 23 | $532 |
| TG Therapeutics, Inc. | 12 | $493 |
| Mallinckrodt Enterprises LLC | 4 | $200 |
| Amgen(2 entities) | 9 | $163 |
| Dexcom, Inc. | 1 | $158 |
| Sunovion Pharmaceuticals Inc. | 7 | $136 |
| Lilly USA, LLC | 7 | $127 |
| Teva Pharmaceuticals USA, Inc. | 8 | $123 |
| Pfizer | 5 | $104 |
| Bristol Myers Squibb | 1 | $95 |
| Neurocrine Biosciences, Inc. | 5 | $93 |
| Eisai Inc. | 4 | $80 |
| Genentech, Inc. | 2 | $79 |
| AstraZeneca | 4 | $72 |
| Acadia Pharmaceuticals Inc | 4 | $70 |
| Lundbeck LLC | 3 | $70 |
| Acorda Therapeutics, Inc | 4 | $66 |
| Sanofi-aventis U.S. LLC | 1 | $66 |
| SK Life Science, Inc. | 3 | $56 |
| Supernus Pharmaceuticals, Inc. | 3 | $48 |
| Grifols USA, LLC | 2 | $44 |
| Biohaven Pharmaceuticals, Inc. | 3 | $42 |
| Greenwich Biosciences, Inc. | 2 | $40 |
| GE HealthCare | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Neurelis, Inc. | 1 | $21 |
| Life Molecular Imaging Ltd | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Avion Pharmaceuticals | 1 | $16 |
| Tanabe Pharma America, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Impel Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCREVUS$11,314
- AUBAGIO$7,247
- VYVGART HYTRULO$6,121
- Mavenclad$4,998
- TYSABRI$2,620
- Vumerity$1,632
- DEXCOM G7 GSS (161)$158
- DEXCOM STELO GLUCOSE BIOSENSOR$158
- BOTOX$126
- ACTHAR$125
- BRIUMVI$121
- AVONEX$113
How this compares
$49,911 in reported general payments places this provider in the 90th percentile of 69 neurology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 82 | $753,961 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 27 | $297,977 |
| Avonex (4 Pack)Interferon Beta-1a | 28 | $244,314 |
| RebifInterferon Beta-1a/Albumin | 24 | $235,541 |
| Plegridy PenPeginterferon Beta-1a | 25 | $202,513 |
| AubagioTeriflunomide | 19 | $174,988 |
| IngrezzaValbenazine Tosylate | 20 | $169,679 |
| TecfideraDimethyl Fumarate | 12 | $130,379 |
| CopaxoneGlatiramer Acetate | 19 | $122,205 |
| Nurtec OdtRimegepant Sulfate | 83 | $112,436 |
| VumerityDiroximel Fumarate | 12 | $97,413 |
| AmpyraDalfampridine | 20 | $82,034 |
| Aimovig AutoinjectorErenumab-Aooe | 98 | $76,257 |
| Emgality PenGalcanezumab-Gnlm | 94 | $74,093 |
| QuliptaAtogepant | 57 | $63,116 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenAvonex (4 Pack), Tecfidera, Vumerity | $10,291 | $472,10652 claims |
| EMD Serono, Inc.Rebif | $8,537 | $235,54124 claims |
| SanofiAubagio | $8,348 | $174,98819 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $93 | $169,67920 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $123 | $122,20519 claims |
| PfizerNurtec Odt, Eliquis | $104 | $121,71296 claims |
| AbbVieQulipta, Ubrelvy | $1,662 | $116,36793 claims |
| Acorda Therapeutics, IncAmpyra | $66 | $82,03420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 69 neurology providers in Maine.
Other neurology in South Portland
- Natalie StecSouth Portland$23
- Anthony KnoxYork$380K
- John DolanPortland$370K
- Heidi HenningerScarborough$350K
- Aashoo MentreddiYork$176K
- Alexander AbudRockport$113K
- Alexandra DegenhardtRockport$65K
- Helia MaghziScarborough$37K
- Edward DrasbyScarborough$22K
- Mitchell RossAuburn$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.